Iraqi Postgraduate Medical Journal

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

Copyrights and Licensing

Home

About Journal

Aim and Scope

Editorial Board

Peer Review Process

Copyrights and Licensing

Indexing and Abstracting

Plagiarism Policy

Author's Guide

Article processing charge (APC)

Immunohistochemical Expression of Estrogen and Progesterone Receptors in Endometrial Carcinoma in Relation to Clinic-Pathological Parameters

,

Document Type : Review Article

Abstract

BACKGROUND:
Carcinoma of the endometrium is the most common gynecologic malignancy in developed countries. Estrogen and progesterone receptors are present in most cases of endometrial adenocarcinoma of endometrioid type, with low-grade tumors being almost invariably positive.
OBJECTIVE:
Evaluation of estrogen and progesterone receptors expression in endometrial carcinoma and their correlation with age, grade and stage of tumor.
MATERIALS AND METHODS:
This is a retrospective study using data collected form archived materials from Teaching Laboratories of Baghdad Medical City ,the period of the study (from February 2020 to December 2020) including formalin fixed, paraffin embedded tissue blocks. Three sections of 5µm thickness were taken from each block, the first was stained with (H&E) for histological revision, the second section was stained for ER and the third section was stained for PR to determine the signal specificity.
RESULTS:
Twenty five cases of endometrial adenocarcinoma were studied. In this study, the peak incidence of endometrial carcinoma was found to be in the range of (61-70) years old. Most cases showed grade I (40%) and grade II (44%). Seventy two percent were positive for estrogen receptor and (60%) of all tumors reacted positively for progesterone receptor. Co-expression of both estrogen receptor and progesterone receptor were noted in (52%) of cases.
CONCLUSION:
Majority of cases with endometrial carcinoma were found to be of grade I and grade II (low grade) and confined to the uterus (stage I & II) at time of diagnosis and most of them express ER and PR and half of the cases express both.
 
 

Keywords

References
  1. Voigt LF, Weiss NS. Epidemiology of endometrial cancer. Cancer Treat Res. 1989;49:1-21.
  2. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640-49.
  3. de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer. 2017;72:215-25.
  4. Hafezi S, Nofech-Mozes S, Ismiil N, et al. Endometrioid endometrial adenocarcinoma (EEA) in elderly women: a clinic-pathologic study. Lab Invest. 2009;89: 216A.
  5. Brustein S, Fruchter R, Greene GL, Pertschuk LP. Immunocytochemical assay of progesterone receptors in paraffin-embedded specimens of endometrial carcinoma and hyperplasia. A preliminary evaluation. Mod Pathol. 1989;2:449-55.
  6. Hye- Rim Lee , Tae-Hee Kim,functions and physiological roles of two types of estrogen receptors , ER-a and ERB; 2012.
  7. scoring and reporting of estrogen receptor (ER) and progesterone receptor (PR) testing.Lab CE ; presented by media lab.
  8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  9. Dossus, N. Allen, R. Kaaks et al., “Reproductive risk factors and endometrial cancer: the european prospective investigation into cancer and nutrition,” International Journal of Cancer, 2010;127: 442–51.
  10. -H. Xu, Y.-B. Xiang, Z.-X. Ruan et al., “Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban shanghai,” International Journal of Cancer, 2004;108: 613–19.
  11. Trentham-Dietz, H. B. Nichols, J. M. Hampton, and P. A. Newcomb, “Weight change
    and risk of endometrial cancer,” International Journal of Epidemiology, 2006;35:151–58.
  12. J. Wernli, R. M. Ray, D. L. Gao, A. J. De Roos, H. Checkoway, and D. B. Thomas,
    “Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese
    women,” Cancer Causes & Control, 2006;17: 949–55.
  13. W. Setiawan, M. C. Pike, L. N. Kolonel, A. M. Nomura, M. T. Goodman, and B. E.
    Henderson, “Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort
    study,” American Journal of Epidemiology, 2007;165: 262–70.
  14. Zucchetto, D. Serraino, J. Polesel et al., “Hormone-related factors and gynecological
    conditions in relation to endometrial cancer risk,” European Journal of Cancer Prevention, 2009;18:316–21.
  15. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical
    pathologic spread patterns of endometrial cancer. A gynecologic oncology group
    Cancer. 1987;60:2035–41.
  16. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: a study of a total
    Cancer. 1991;67:3093–103.
  17. Eur J Gynaecol Oncol. Using FIGO histologic grade to determine when to perform
    lymphadenectomies in endometrioid adenocarcinoma of the endometrium. 1996;17:204-7.
  18. KHUSHBAKHAT R. MITTAL, Architectural (FIGO) Grading, Nuclear Grading, and Other
    Prognostic Indicators in Stage I Endometrial Adenocarcinoma With Identification of High-Risk and Low-Risk Groups. 1988;61:538-45.
  19. J Turk Ger Gynecol Assoc. comparison of preoperative endometrial biopsy grade and final
    pathologic diagnosis in patients with endometrioid endometrial cancer. 2012; 13: 106–10.
  20. Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, Haie-Meder C, Thomas L, Quénel-Tueux N, Daraï E, Dorangeon PH, Marret H, Taïeb S, Mazeau-Woynar V; Institut National duCancer; Societe Francaise d’Oncologie Gynecologique: Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Societe Francaise d’Oncologie Gynecologique. Int J Gynecol Cancer 2011;21: 945- 50.
  21. Ballester M, Naoura I, Chereau E, Seror J, Bats AS, Bricou A and Daraï E: Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study. Ann Surg Oncol 2012;20: 407-12.
  22. ANDREW BERCHUCK , M.D.Pastsurgical surveillance of patients with stage I\II endometrial adenocarcinoma . 1995;59:20-24.
  23. A. Elshaikh, R. Cattaneo II, G. Jacobsen, and R. Hanna; Henry Ford Health System, Detroit, MI. Interval Between Hysterectomy and Start of Radiation Treatment is Predictive of Recurrence in Patients With Endometrial Carcinoma – A Single Institution Experience . 2012; 84 : 3S Supplement.
  24. F. Dunn, V. Gondi, K.A. Bradley, C.S. Platta, and B.M. Anderson; University of Wisconsin, Madison, WI . Predictive Factors for Re Volume 84 Number 3S Supplement 2012.currence Following Postoperative Vaginal Cuff Brachytherapy Alone for Stage I Endometrial Cancer .
  25. Kumari PR, Renuka IV, Apuroopa M, Chaganti PD. A study of expression of estrogen and progesterone receptor, in atrophic, hyperplastic and malignant endometrial lesions, with emphasis on relationship with prognostic parameters. Int J Res Med Sci 2015;3:3318-25.
  26. Shen F, Gao Y, Ding J, Chen Q. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget. 2017;8: 506-11. doi:10.18632/oncotarget.13471.
  27. Deborah Smith , ER and PR expression and survival after endometrial cancer. 22 November 2017.
  28. Caifeng Wang, Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer. 2020;11:1693-701.
  29. Nayar Musfera Abdul Masjeed1,Immunohistochemical Study of ER, PR, Ki67 and p53 in
    Endometrial Hyperplasias and Endometrial Carcinomas. 10.7860/JCDR/2017/28750.10475.
  30. Yue Wang, M.S.,Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer . 00:1–8, Lippincott Williams & Wilkins, Baltimore.Copyright © 2018 by the International Society of Gynecological Pathologists.
  31. Jun Guan ,The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol. 2019;30:e13.
  32. Kerner H, Sabo E, Friedman M, Beck D, Samare O, Lichtig C: An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer. 1995;5:275-81. 10.1046/j.1525- 1438.1995.05040275.x.
  33. Markman M: Hormonal therapy of endometrial cancer. Eur J Cancer. 2005;41:673-75. 10.1016/j.ejca.2004.12.008.
  34. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13: 379-88. 10.1038/modpathol.3880062.
  35. Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakır C, Sensu S, Karadayi N: The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol. 2010;5:13-10.1186/1746- 1596-5-13.
  36. GEOFFROY CANLORBE Contribution of Immunohistochemical Profile in Assessing Histological Grade of Endometrial Cancer. ANTICANCER RESEARCH 2013;33: 2191-98.
  37. Caifeng Wang, Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer, J Cancer. 2020;11:1693–701.
  38. Utaaker E, Iversen OE, Skaarland E: The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89–100.
  39. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986;46:5419–25.
  40. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990;94:247–54.
  41. Mutch DG, Soper JT, Budwit-Novotny DA, Cox EB, Creasman WT,McCarty KS Jr: Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. centre study into the reliability of steroid receptor immunocytochemical Am J Obstet Gynecol 1987;157:924–31.
  42. Kadar N, Malfetano JH, Homesley HD: Steroid receptor concentrations in endometrial carcinoma: Effect on survival in surgically staged patients. Gynecol Oncol 50:281 –286, 1993.
  43. Chambers JT, MacLusky N, Eisenfield A, Kohorn E, Lawrence R Schwartz PE: Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988;31:65–81.
  44. Kauppila A, Kujansuu E, Vihko R: Cytosol estrogen and progestin receptors in endometrial carcinoma in patients treated with surgery,radiotherapy, and progestin: clinical correlates. Cancer 1982;50:2157–62.
  45. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133‒38.
  46. Soper JT, McCarty KS, Creasman WT, ClarkePearson DL, McCarty KS: Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gyneco. 1984;150: 437- 39. 10.1016/S0002-9378(84)80159-3. 
Iraqi Postgraduate Medical Journal
Volume 22, Issue 4
October 2023
Page 407-416
Files
Share
Export Citation
Statistics